Pair Name | Narirutin, Cisplatin | ||
Phytochemical Name | Narirutin (PubChem CID: 442431 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Drug Name | Cisplatin |
Adverse Reactions | Myelosuppression, dry mouth and throat, fever, dry stools. This was inferred hot nature anticancer drug. |
Recommendations | Cold: Anemarrhena asphodeloides; Urena lobataL; Artemisia scoparia; Swertia mussotii; Swertia pseudochinensis; Gentiana manshurica; Gossampinus malabarica; Pyrrosia sheareri; Pyrrosia sheareri; Iris domestica; Gentiana scabra; Pyrrosia sheareri; Pyrrosia petiolosa |
Reference | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. ref_link |
Pair Name | Narirutin, Cisplatin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Ion channel protein | |||
Gene Regulation | Down-regulation | Expression | ANO1 | hsa55107 |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Up-regulation | Expression | CDH1 | hsa999 | |
Down-regulation | Expression | CDH2 | hsa1000 | |
Down-regulation | Phosphorylation | MAP2K7 | hsa5609 | |
Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Down-regulation | Expression | VIM | hsa7431 | |
In Vitro Model | LA-795 | Adenocarcinoma of the mouse pulmonary system | Mus musculus (Mouse) | CVCL_G363 |
In Vivo Model | LA795 cells were inoculated to Balb/c mice (6- to 8-week-old) in the right forelimb. Tumor volumes were measured every 5 day. | |||
Result | Based on the significant anticancer effect and high biosafety, naringin has great potential as a functional food in the adjuvant treatment of lung cancer. |
No. | Title | Href |
---|---|---|
1 | Molecular mechanism of ion channel protein TMEM16A regulated by natural product of narirutin for lung cancer adjuvant treatment. Int J Biol Macromol. 2022 Dec 31;223(Pt A):1145-1157. doi: 10.1016/j.ijbiomac.2022.11.123. | Click |